This acquisition comes as GSK looks to stock up its pipeline amid the looming patent expiries soon to impact the company’s portfolio.

GSK committed $270 million up front in recent months to gain access to early-stage assets in the class of cancer therapies known as antibody drug conjugates, or ADCs. The deals are part of a broad ...

This deal adds two more siRNA candidates to GSK’s pipeline, which the company is looking to expand as it looks to offset the ...

GSK acquires 35Pharma for $950M. The primary focus is HS235, a selective PH drug reducing bleeding risk with metabolic ...

Pharmaceutical company GSK has paid $70 million to partner with precision medicine company Tempus. Through the partnership, GSK will have access to Tempus’ artificial intelligence platform and ...

is using emerging radio frequency identification (RFID) technology as part of a pilot program to crack down on drug counterfeiting and to protect consumers. GSK said Wednesday that bottles of its HIV ...

Settlement reached over mRNA-based COVID vaccines CureVac and GSK get $740 million upfront, and royalties BioNTech's deal to buy CureVac on track GSK's own lawsuits against Pfizer, BioNTech unaffected ...

GSK (GlaxoSmithKline Plc) is ramping up its US presence with a multi-billion-dollar plan to expand research and development (R&D) and manufacturing capabilities across the country. “Today, we are ...

Shortly after winning a stay on a COVID-19 vaccine patent lawsuit brought by Moderna, Pfizer and its German partner BioNTech are being dragged into another round of mRNA litigation by GSK. GSK on ...